Mike Mensinger serves as Chief Product Officer at Beta Bionics Inc., a pioneering medical technology company revolutionizing diabetes management with its FDA-cleared iLet Bionic Pancreas. In this role, he leads the product strategy, development, and commercialization efforts, ensuring the bionic pancreas system—known for its fully automated insulin dosing with minimal user input—continues to evolve to improve outcomes for people with diabetes. Mensinger's oversight extends to user experience, regulatory compliance, and integration of advanced algorithms, drawing on his deep expertise to drive innovation in automated insulin delivery systems. With over two decades in the medical device industry, Mensinger has held pivotal leadership positions at leading diabetes technology firms. Previously, as Vice President of Product Development at Tandem Diabetes Care, he spearheaded the creation of the t:slim X2 insulin pump, the world's first pump with Basal-IQ predictive low-glucose suspend technology, which earned FDA clearance and transformed user safety. Earlier roles at Dexcom and Animas Corporation honed his skills in continuous glucose monitoring and insulin pump design, where he contributed to multiple product launches that advanced closed-loop systems and earned industry accolades, including JDRF awards for innovation. Mensinger's achievements include numerous patents in glucose-responsive insulin delivery and a track record of bringing user-centric products to market that have benefited millions living with type 1 diabetes. His strategic vision at Beta Bionics emphasizes simplifying therapy burdens, fostering collaborations with clinicians and patients to refine features like emoji-based initialization, positioning the company as a leader in bionic endocrinology.